HK1256367A1 - 使用b-raf抑制劑和免疫檢查點抑制劑治療癌症的方法 - Google Patents

使用b-raf抑制劑和免疫檢查點抑制劑治療癌症的方法

Info

Publication number
HK1256367A1
HK1256367A1 HK18115456.5A HK18115456A HK1256367A1 HK 1256367 A1 HK1256367 A1 HK 1256367A1 HK 18115456 A HK18115456 A HK 18115456A HK 1256367 A1 HK1256367 A1 HK 1256367A1
Authority
HK
Hong Kong
Prior art keywords
inhibitors
methods
treating cancer
immune checkpoint
raf
Prior art date
Application number
HK18115456.5A
Other languages
English (en)
Inventor
Dawn Colburn
Nicole Richie
Original Assignee
豪夫邁‧羅氏有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 豪夫邁‧羅氏有限公司 filed Critical 豪夫邁‧羅氏有限公司
Publication of HK1256367A1 publication Critical patent/HK1256367A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
HK18115456.5A 2015-11-19 2018-12-04 使用b-raf抑制劑和免疫檢查點抑制劑治療癌症的方法 HK1256367A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562257645P 2015-11-19 2015-11-19
PCT/US2016/062859 WO2017087851A1 (en) 2015-11-19 2016-11-18 Methods of treating cancer using b-raf inhibitors and immune checkpoint inhibitors

Publications (1)

Publication Number Publication Date
HK1256367A1 true HK1256367A1 (zh) 2019-09-20

Family

ID=57485956

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18115456.5A HK1256367A1 (zh) 2015-11-19 2018-12-04 使用b-raf抑制劑和免疫檢查點抑制劑治療癌症的方法

Country Status (13)

Country Link
US (3) US20180256552A1 (zh)
EP (1) EP3377107B1 (zh)
JP (1) JP6952691B2 (zh)
KR (1) KR102702851B1 (zh)
CN (1) CN108136022A (zh)
AU (1) AU2016355320B2 (zh)
CA (1) CA3004348A1 (zh)
ES (1) ES2824120T3 (zh)
HK (1) HK1256367A1 (zh)
IL (1) IL259055B (zh)
MX (1) MX2018006152A (zh)
PL (1) PL3377107T3 (zh)
WO (1) WO2017087851A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017011644A (es) 2015-03-13 2017-12-04 Cytomx Therapeutics Inc Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
KR101997241B1 (ko) 2015-05-21 2019-07-09 하푼 테라퓨틱스, 인크. 삼중특이성 결합 단백질 및 사용 방법
ES2837428T3 (es) 2016-01-08 2021-06-30 Hoffmann La Roche Procedimientos de tratamiento de cánceres positivos para CEA usando antagonistas de unión al eje PD-1 y anticuerpos biespecíficos anti-CEA/anti-CD3
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
NZ759442A (en) * 2017-06-01 2024-07-05 Cytomx Therapeutics Inc Activatable anti-pdl1 antibodies, and methods of use thereof
CR20200195A (es) 2017-10-13 2020-08-14 Harpoon Therapeutics Inc Proteínas de unión a antigenos de maduraciòn de celulas b
KR20210086623A (ko) 2018-09-25 2021-07-08 하푼 테라퓨틱스, 인크. Ddl3 결합 단백질 및 사용 방법
EP3867409A1 (en) * 2018-10-16 2021-08-25 Novartis AG Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
WO2021016228A1 (en) * 2019-07-22 2021-01-28 H. Lee Moffitt Cancer Center And Research Institute Inc. Combination therapy for treating ras-mutant cancers
WO2022131667A1 (ko) * 2020-12-18 2022-06-23 경희대학교 산학협력단 Oligodendrocyte transcription factor 2 억제제를 유효성분으로 포함하는 흑색종 치료 효과 증진용 약학적 조성물
JP2024513246A (ja) * 2021-04-09 2024-03-22 ジェネンテック， インコーポレイテッド Ｒａｆ阻害剤及びｐｄ－１軸阻害剤を用いた併用治療
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
KR101339628B1 (ko) 2005-05-09 2013-12-09 메다렉스, 인코포레이티드 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
EP1893612B1 (en) 2005-06-22 2011-08-03 Plexxikon, Inc. Pyrrolo [2, 3-b]pyridine derivatives as protein kinase inhibitors
DK1907424T3 (en) 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
RS51782B (en) 2005-10-07 2011-12-31 Exelixis Inc. AZETIDINS AS MAK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
RU2531758C2 (ru) 2008-02-11 2014-10-27 Куретек Лтд. Моноклональные антитела для лечения опухолей
KR20100122505A (ko) 2008-02-29 2010-11-22 어레이 바이오파마 인크. Ｒａｆ 저해물질 화합물 및 이들의 이용 방법
EP2265609B1 (en) 2008-02-29 2012-09-05 Array Biopharma, Inc. Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors
WO2009111280A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
AR072657A1 (es) 2008-02-29 2010-09-15 Genentech Inc Compuestos inhibidores de raf y metodos para su uso
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
CA2735006A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
CN114835812A (zh) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
HUE049647T2 (hu) 2009-11-24 2020-09-28 Medimmune Ltd Targetált kötõdõ ágensek B7-H1 ellen
SG11201500582UA (en) * 2012-08-17 2015-04-29 Hoffmann La Roche Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
WO2014193898A1 (en) * 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Combination therapies for cancer
TN2015000444A1 (en) * 2013-06-03 2017-04-06 Novartis Ag Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor

Also Published As

Publication number Publication date
PL3377107T3 (pl) 2020-12-14
US20200155520A1 (en) 2020-05-21
WO2017087851A1 (en) 2017-05-26
CA3004348A1 (en) 2017-05-26
MX2018006152A (es) 2018-09-17
AU2016355320A1 (en) 2018-05-17
JP6952691B2 (ja) 2021-10-20
EP3377107B1 (en) 2020-08-12
IL259055B (en) 2022-05-01
US20240115555A1 (en) 2024-04-11
KR20180081591A (ko) 2018-07-16
EP3377107A1 (en) 2018-09-26
US20180256552A1 (en) 2018-09-13
AU2016355320B2 (en) 2023-12-07
JP2018534311A (ja) 2018-11-22
IL259055A (en) 2018-06-28
KR102702851B1 (ko) 2024-09-05
ES2824120T3 (es) 2021-05-11
CN108136022A (zh) 2018-06-08

Similar Documents

Publication Publication Date Title
HK1256367A1 (zh) 使用b-raf抑制劑和免疫檢查點抑制劑治療癌症的方法
IL249658A0 (en) Methods of treating cancer using tigit inhibitors and anticancer agents
IL283908A (en) A method of treating cancer by inhibiting an immune checkpoint in combination with an additional therapeutic agent
PT3322731T (pt) Método de tratamento de cancro utilizando inibidor de ponto de verificação (checkpoint) imunitário; anticorpo que se liga ao recetor de morte programada-1 (pd-1) ou ligando de morte programada 1 (pd-l1)
HK1253093A1 (zh) 診斷和治療癌症的方法
HK1256380A1 (zh) 修飾的細胞和治療方法
HK1251409A1 (zh) 治療癌症的方法
IL251669A0 (en) Cancer treatment using a tlr9 agonist with checkpoint inhibitors
HK1251862A1 (zh) 治療癌症的方法和組合物
HK1254954A1 (zh) Lpt-723和免疫檢查點抑制劑組合物及其治療方法
RS62007B1 (sr) Postupci pojačavanja tonične inhibicije i lečenja angelmanovog sindroma
IL259801A (en) ezh2 inhibitors and methods of using them
IL273196A (en) Claudin 6 antibodies and methods of cancer treatment
HK1243407A1 (zh) Ripk2抑制劑及用其治療癌症的方法
HK1251927A1 (zh) 用於治療癌症的新穎生物標記和方法
GB201709076D0 (en) Parp inhibitors for use in methods of treating cancer
HUE058190T2 (hu) Enoláz inhibitorok és ezekkel történõ kezelési eljárások
GB201418640D0 (en) Agents and methods for treatment of cancer